

GLOBAL MARKETS FOR INFECTIOUS DISEASE TREATMENTS



PHM061C
January 2016

Peggy Lehr
Project Analyst

ISBN: 1-62296-193-5



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	3
INTENDED AUDIENCE	3
METHODOLOGIES AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)</i>	7
CHAPTER 3 OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES AND TREATMENT	10
TOP GLOBAL CAUSES OF DEATH	10
<i>TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)</i>	11
MAJOR INFECTIOUS DISEASES	11
<i>TABLE 2 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)</i>	12
HISTORICAL IMPACT OF INFECTIOUS DISEASES	12
LEADING CAUSES OF GLOBAL DEATHS	13
Transmission of Infectious Diseases	13
LINKING INFECTIOUS DISEASE TO CANCER	13
TREATMENTS FOR INFECTIOUS DISEASES	13
PREVENTION	13
VACCINATION	14
WHO Global Vaccination Action Plan	14
<i>FIGURE 1 GLOBAL IMMUNIZATION COVERAGE, 2014 (%)</i>	14
Challenges to Meet WHO Guidelines	15
GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET	16
TYPES OF DIAGNOSTIC TESTING	16
FLUORESCENT IMMUNOASSAY (FIA)	16
Direct Fluorescent Antibody Testing (FA)	17
Indirect Fluorescent Antibody Testing (IFA)	17
ENZYME IMMUNOASSAY (EIA)	17
Basic EIA	17
Enzyme-Linked Immunosorbent Assay (ELISA)	18
GENE PROBE ANALYSIS	18
Polymerase Chain Reaction Amplification (PCR)	18
Nucleic Acid Amplification Test (NAT)	19

TOPIC	PAGE NO.
Transcription-Mediated Amplification (TMA)	19
Nucleic Acid Sequence-Based Amplification (NASBA)	19
GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS	20
<i>TABLE 3 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	20
GLOBAL INFECTIOUS DISEASE VACCINE MARKET	20
<i>TABLE 4 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	21
GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET	21
<i>TABLE 5 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	21
VACCINE OPPORTUNITIES	21
CHILDHOOD DISEASES	21
GLOBAL HUMANITARIAN AGENCIES	22
PHARMACEUTICAL OPPORTUNITIES	22
THE EMERGENCE OF GENE THERAPY	22
MERGERS AND ACQUISITIONS	23
<i>TABLE 6 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 (\$ MILLIONS)</i>	23
CHAPTER 4 VACCINES - THE PRESENT AND THE FUTURE	26
VACCINES AND PATENTS	26
MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES	26
<i>TABLE 7 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	27
<i>TABLE 8 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE, THROUGH 2021 (\$ MILLIONS)</i>	27
TYPES OF VACCINES	27
LIVE ATTENUATED VACCINE	27
INACTIVATED VACCINE	28
Acellular/Subunit Vaccines	28
IMMUNITY	28
INNATE IMMUNITY	28
ACQUIRED IMMUNITY	28
The Activity of T Cells	29
Acquired Immunity - Cell-Mediated Response	29
LASTING IMMUNITY	30
VIRAL DISEASES PREVENTED BY VACCINE	30
<i>TABLE 9 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES</i>	30
BACTERIAL DISEASES PREVENTED BY VACCINE	31
<i>TABLE 10 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES</i>	31
VACCINATION SCHEDULES FOR CHILDREN IN THE U.S.	32
<i>TABLE 11 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS IN THE U.S.</i>	32
<i>TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS, TO 4 YEARS TO 6 YEARS IN THE U.S.</i>	32
<i>TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 YEARS TO 18 YEARS IN THE U.S.</i>	33
CONCERNS REGARDING VACCINATION IN CHILDHOOD	33
NUMBER OF INOCULATIONS	33

TOPIC	PAGE NO.
RECOGNIZING IMMUNE RESPONSE	34
IMMUNIZATION AND WEAKENED OR ALTERED IMMUNE SYSTEMS	34
HEPATITIS B VACCINATIONS THROUGH WHO GUIDELINES	34
VACCINE PRODUCTION	34
<i>FIGURE 2 VACCINE MANUFACTURING PROCESS</i>	35
VACCINE MANUFACTURERS	35
<i>FIGURE 3 GLOBAL VACCINE MANUFACTURING MARKET, 2014 (%)</i>	35
CHANGES IN MANUFACTURING LANDSCAPE	36
TOP-SELLING VACCINES OF 2014	37
<i>TABLE 14 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2014</i>	37
GLOBAL VACCINATION EFFORTS	37
REGIONAL ANALYSIS	38
<i>TABLE 15 REGIONAL MARKETS FOR VACCINES, THROUGH 2021 (\$ MILLIONS)</i>	38
<i>FIGURE 4 REGIONAL MARKET SHARE FOR VACCINES, 2016 AND 2021 (%)</i>	38
THE AMERICAS	39
<i>TABLE 16 AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	40
EMRA	40
<i>TABLE 17 EMRA MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	40
ASIA	41
<i>TABLE 18 ASIAN MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	41
TRENDS IN VACCINE DEVELOPMENT	42
ADJUVANT DEVELOPMENT	42
COMBINATION VACCINES	42
INHALED OR INTRANASAL VACCINE ADMINISTRATION	43
NEED FOR RAPID RESPONSE TIMES	43
Real-Time Detection	43
CHAPTER 5 VIRAL INFECTIOUS DISEASES	46
GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS	46
<i>TABLE 19 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	46
PATENT PROTECTION	47
<i>TABLE 20 PATENT EXPIRY BY PRODUCT, INDICATION, MANUFACTURER AND DATE OF PATENT EXPIRY</i>	47
HEPATITIS B AND C	48
MARKET FOR HBV AND HCV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS	48
<i>TABLE 21 GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	48
DIAGNOSIS	48
<i>TABLE 22 GLOBAL MARKET SHARE FOR HEPATITIS B AND C DIAGNOSTIC PRODUCT BY TYPE OF TEST AND REVENUES, 2015 (\$ MILLIONS/%)</i>	49
<i>TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2015</i>	49
Automated Infectious Disease Testing for Hepatitis	51

TOPIC	PAGE NO.
TREATMENT MARKET	51
TABLE 24 GLOBAL MARKET FOR HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2015 (\$ MILLIONS/RANK)	51
FIGURE 5 GLOBAL MARKET SHARE FOR TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET, 2015 (%)	52
TABLE 25 PHARMACEUTICALS FOR THE TREATMENT OF HEPATITIS B AND C, 2015	53
NEWEST PHARMACEUTICALS TO TREAT HBV AND HCV	54
Additional Competitor	54
MARKET FOR DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS TO TREAT HBV AND HCV	54
TABLE 26 GLOBAL MARKET FOR HBV AND HCV PHARMACEUTICALS, THROUGH 2021 (\$ MILLIONS)	54
RISK FACTORS	54
GEOGRAPHICAL DISTRIBUTION	55
HERPES SIMPLEX VIRUS	55
TABLE 27 GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	55
INCIDENCE	56
DIAGNOSIS	56
TABLE 28 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HSV BY BRAND NAME, TYPE AND MANUFACTURER, 2015	56
TREATMENT	57
TABLE 29 DRUGS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER	57
HIV/AIDS	57
TABLE 30 GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	58
RISK FACTORS	58
INCIDENCE/MORTALITY	59
ANTIRETROVIRAL THERAPY (ART)	59
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)	59
TABLE 31 COMBINATION DRUGS APPROVED FOR HAART	59
HAART Failure	61
Mega-HAART	61
"TREATMENT FOR ALL" WHO PROGRAM	61
COUNT <800 CELLS/MEDICATIONS	61
Pre-Exposure Prophylaxis	61
CLINICAL TRIALS FOR HIV VACCINE AND MEDICATIONS	62
HUMAN PAPILOMAVIRUS	62
TABLE 32 GLOBAL MARKET FOR HPV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	63
HPV AND CANCER	63
TABLE 33 CANCERS LINKED TO HPV INFECTION, BY TYPE AND PERCENT OF FREQUENCY	63
INCIDENCE	63
SYMPTOMS	64
DIAGNOSIS	64
TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2015	64
TREATMENT	65

TOPIC	PAGE NO.
<i>TABLE 35 DRUGS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	65
INFLUENZA A AND B	65
VACCINE	65
TREATMENT	66
CHILDHOOD DISEASES	66
MEASLES	66
MUMPS	66
POLIO	67
VIRAL PNEUMONIA	67
Treatment	67
ROTAVIRUS	67
DEHYDRATION	68
ZINC	68
RSV	68
SYMPTOMS	68
DIAGNOSTIC PRODUCTS	69
<i>TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE, 2015</i>	69
VIRAL DIAGNOSTIC PRODUCTS	69
<i>TABLE 37 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	70
VIRAL PHARMACEUTICAL PRODUCTS	70
<i>TABLE 38 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	70
REGIONAL ANALYSIS	71
<i>TABLE 39 REGIONAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	71
<i>FIGURE 6 REGIONAL MARKET SHARE FOR VIRAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)</i>	72
<i>TABLE 40 REGIONAL MARKET FOR VIRAL DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	73
<i>TABLE 41 REGIONAL MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	73
AMERICAS	73
Hepatitis B in the U.S.	73
Hepatitis C in the U.S.	74
Market for Viral Infectious Disease Products in the Americas	74
<i>TABLE 42 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	74
<i>TABLE 43 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	74
EMRA	75
Hepatitis C	75
Hepatitis in Africa	75
Hepatitis in Russia, Eurasia	76
Russian Pharmaceutical Regulations	76
Market for Viral Infectious Disease Diagnostic Products	76
<i>TABLE 44 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	76

TOPIC	PAGE NO.
<i>TABLE 45 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	77
ASIA	77
Hepatitis in Asian Region	77
<i>TABLE 46 CURRENTLY USED HEPATITIS DRUGS IN THE SOUTHEAST ASIAN REGION, BY PERCENT OF USE, 2012*</i>	78
Hepatitis in Japan	78
Hepatitis in China	78
Hepatitis in India	79
HIV in Japan	79
HIV in India	79
HIV in China	80
<i>TABLE 47 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	80
<i>TABLE 48 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	81
CHAPTER 6 BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC RESISTANCE	83
NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES	83
<i>TABLE 49 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES</i>	83
MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS	83
<i>TABLE 50 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	84
MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS	84
<i>TABLE 51 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2021 (\$ MILLIONS)</i>	84
MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS	85
<i>TABLE 52 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2021 (\$ MILLIONS)</i>	85
NOTABLE BACTERIAL DISEASES	86
SEXUALLY TRANSMITTED DISEASES	86
Chlamydia	86
INCIDENCE	86
DIAGNOSTIC PROCEDURES	86
<i>TABLE 53 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND MANUFACTURER, 2015</i>	87
TREATMENTS	88
<i>TABLE 54 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA</i>	88
Gonorrhea	89
Diagnostic Product Market	89
<i>TABLE 55 GONORRHEA DIAGNOSTIC PRODUCT AND MANUFACTURERS</i>	89
Treatment Market	90
<i>TABLE 56 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS</i>	90
Syphilis	90
<i>TABLE 57 STAGES OF SYPHILIS</i>	91
Risk Factors	91
Incidence	91

TOPIC	PAGE NO.
Diagnostic Products	92
<i>TABLE 58 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	92
TREATMENTS	93
BACTERIAL PNEUMONIA	93
Treatment	93
CORYNEBACTERIUM DIPHTHERIAE, CLOSTRIDIUM TETANI, BORDETELLA PERTUSSIS	93
Diphtheria	93
Tetanus	93
Pertussis	94
MENINGITIS	94
MYCOBACTERIUM TUBERCULOSIS (TB)	94
<i>TABLE 59 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	95
Epidemiology of TB	95
Geographic Prevalence	96
<i>TABLE 60 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	96
ANTIBIOTIC DEVELOPMENT	96
<i>TABLE 61 ANTIBIOTICS: YEAR OF INTRODUCTION, YEAR OF RESISTANCE OBSERVED, MODE OF ACTION AND TARGET SPECIES</i>	97
ANTIBIOTIC RESISTANCE	98
MECHANISMS OF RESISTANCE	98
METHODS OF RESISTANCE	99
Beta-Lactamase Production	99
Importing Resistance from Other Organisms	100
Examples of Antibiotic-Resistant Bacteria	100
Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness	101
Antibiotic Discharge	101
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE	101
Failure to Finish Antibiotic Courses	101
Antibiotic Overuse	101
Agricultural Practices	102
<i>TABLE 62 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009* (POUNDS/%)</i>	103
Patient Pressure	103
RESISTANCE BY CLASS OF ANTIBIOTIC	103
<i>TABLE 63 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED</i>	104
INCIDENCES OF ANTIBIOTIC RESISTANCE	104
ANTIBIOTIC RESISTANCE IN EUROPE	104
ANTIBIOTIC RESISTANCE IN THE U.S.	104
MAJOR ANTIBIOTIC-RESISTANT ORGANISMS	104
VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE)	105
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)	105
CLOSTRIDIUM DIFFICILE (C. DIFFICILE)	105
REGIONAL ANALYSIS	106
<i>TABLE 64 REGIONAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	106

TOPIC	PAGE NO.
<i>FIGURE 7 REGIONAL MARKET SHARE FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)</i>	106
THE AMERICAS	107
STDs in the U.S.	107
<i>TABLE 65 AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	108
Bacterial Infection Diagnostic Product Market in the Americas	108
<i>TABLE 66 AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	108
Bacterial Infection Pharmaceutical Market in the Americas	109
<i>TABLE 67 AMERICAS MARKET FOR BACTERIAL INFECTION PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	109
EMRA (EUROPE, MIDDLE EAST, RUSSIA, AFRICA)	109
<i>TABLE 68 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	110
Bacterial Infectious Diseases Diagnostic Market in EMRA	110
<i>TABLE 69 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	110
Bacterial Infectious Diseases Pharmaceutical Product Market in EMRA	110
<i>TABLE 70 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	111
ASIA	111
<i>TABLE 71 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	111
Bacterial Infectious Diseases Diagnostic Product Market in Asia	112
<i>TABLE 72 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	112
Bacterial Infectious Diseases Pharmaceutical Product Market in Asia	112
<i>TABLE 73 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	113
CHAPTER 7 PARASITIC INFECTIOUS DISEASES	115
NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES	115
<i>TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES</i>	115
CLIMATE CHANGE AND VECTOR-BORNE DISEASES	116
MALARIA	116
INCIDENCES OF MALARIA	116
Global Risk for Malaria	117
CAUSES OF MALARIA	117
Symptoms of Malaria	117
GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS	117
<i>TABLE 75 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	117
DIAGNOSIS OF MALARIA	118
<i>TABLE 76 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	118
TREATMENT OF MALARIA	118
<i>TABLE 77 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2015</i>	118

TOPIC	PAGE NO.
<i>TABLE 78 GLOBAL MARKET FOR MALARIAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	119
REGIONAL ANALYSIS	119
<i>TABLE 79 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	120
<i>FIGURE 8 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)</i>	120
THE AMERICAS	121
<i>TABLE 80 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	121
Malarial Diagnostic Product Market in the Americas	121
<i>TABLE 81 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	122
Malarial Pharmaceutical Market in the Americas	122
<i>TABLE 82 AMERICAS MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	122
EMRA	122
<i>TABLE 83 EMRA MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	122
Malarial Diagnostic Product Market in EMRA	123
<i>TABLE 84 EMRA MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	123
Malarial Pharmaceutical Product Market in the EMRA	123
<i>TABLE 85 EMRA MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	123
ASIA	124
<i>TABLE 86 ASIAN MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	124
<i>TABLE 87 ASIAN MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	124
<i>TABLE 88 ASIAN MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	125
<i>TABLE 89 CURRENT AND PARASITIC PHARMACEUTICALS WITH TRADE NAME, GENERIC NAME, MANUFACTURER AND AREA OF TREATMENT, 2014</i>	125
MARKET FOR ANTIPARASITIC PHARMACEUTICALS	126
OPPORTUNITIES IN THE MALARIAL DISEASE MARKET	126
DIAGNOSTIC TESTING	126
CHAPTER 8 EMERGING TECHNOLOGY AND PHARMACEUTICALS	128
GLAXOSMITHKLINE/NOVARTIS TRANSACTION	128
HEPATITIS C	128
<i>TABLE 90 FDA-APPROVED PHARMACEUTICALS TO TREAT HCV, 2011-2015</i>	128
<i>TABLE 91 PHARMACEUTICALS IN CLINICAL TRIALS FOR HCV, 2015</i>	129
<i>FIGURE 9 RESEARCH LANDSCAPE FOR HBV PHARMACEUTICALS BY TYPE, 2015 (%)</i>	130
DENGUE VIRUS VACCINE	130
MALARIA	131
<i>TABLE 92 PHASE II & III PIPELINE FOR MALARIAL TREATMENTS, 2015</i>	131
BASILEA PHARMACEUTICA	131
POLYPHOR	132
REMPEX PHARMA	132

TOPIC	PAGE NO.
HIV	132
ATTACHMENT INHIBITORS	132
GENE MODIFICATION	133
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE	133
<i>TABLE 93 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2015</i>	133
CHAPTER 9 PATENT ANALYSIS	138
PATENT ANALYSIS	138
PATENT EXPIRATIONS	138
<i>TABLE 94 U.S. PHARMACEUTICAL PATENT EXPIRY, 2010-2031</i>	139
PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, DESCRIPTION AND APPROVAL DATE	140
<i>TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, JAN. 2015 TO SEPT. 2015</i>	140
PATENTS ISSUED BY COMPANY	148
<i>TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PRODUCT PATENTS BY COMPANY, JAN. 2015 TO SEPT. 2015</i>	148
INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE	150
<i>TABLE 97 PATENTS ISSUED FOR VACCINE AND TREATMENT OF INFECTIOUS DISEASES BY DISEASE, JAN. 2015 TO SEPT. 2015 (NUMBER/%)</i>	150
<i>TABLE 98 INFECTIOUS DISEASES VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN JAN. 2015 AND SEPT. 2015 (%)</i>	151
CHAPTER 10 COMPANY DIRECTORY	153
ABBOTT LABORATORIES	153
BUSINESS OVERVIEW	153
<i>TABLE 99 ABBOTT PHARMACEUTICAL PRODUCTS</i>	153
PRODUCTS	153
<i>TABLE 100 ABBOTT DIAGNOSTIC PRODUCTS</i>	153
ABBVIE INC.	154
BUSINESS OVERVIEW	154
PRODUCTS	154
<i>TABLE 101 ABBVIE PHARMACEUTICAL PRODUCTS</i>	154
ALLERGAN (FORMERLY ACTAVIS)	154
BUSINESS OVERVIEW	155
PRODUCTS	155
<i>TABLE 102 ALLERGAN PHARMACEUTICAL PRODUCTS</i>	155
ALERE	155
BUSINESS OVERVIEW	155
PRODUCTS	156
<i>TABLE 103 ALERE DIAGNOSTIC PRODUCTS</i>	156
ALFA SCIENTIFIC DESIGNS	157
BUSINESS OVERVIEW	157
PRODUCTS	157
<i>TABLE 104 ALFA SCIENTIFIC DESIGNS' DIAGNOSTIC PRODUCTS</i>	157
ATLAS LINK BIOTECH CO. LTD.	157
BUSINESS OVERVIEW	158
PRODUCTS	158

TOPIC	PAGE NO.
<i>TABLE 105 ATLAS LINK BIOTECH DIAGNOSTIC'S PRODUCTS</i>	158
ASTRAZENECA	158
BUSINESS OVERVIEW	158
PRODUCTS	159
<i>TABLE 106 ASTRAZENECA PHARMACEUTICAL'S PRODUCTS</i>	159
AUROBIND PHARMA LTD.	159
BUSINESS OVERVIEW	159
BAXTER INTERNATIONAL INC.	159
BUSINESS OVERVIEW	160
PRODUCTS	160
<i>TABLE 107 BAXTER PHARMACEUTICAL'S PRODUCTS</i>	160
BAYER AG	160
BUSINESS OVERVIEW	160
PRODUCTS	160
<i>TABLE 108 BAYER PHARMACEUTICAL'S PRODUCTS</i>	160
BECTON DICKINSON	161
BUSINESS OVERVIEW	161
PRODUCTS	161
<i>TABLE 109 BECTON DICKINSON DIAGNOSTIC'S PRODUCTS</i>	161
BIO-RAD LABORATORIES	161
BUSINESS OVERVIEW	162
PRODUCTS	162
<i>TABLE 110 BIO-RAD DIAGNOSTIC'S PRODUCTS</i>	162
BOEHRINGER INGELHEIM GMBH	162
BUSINESS OVERVIEW	162
PRODUCTS	163
<i>TABLE 111 BOEHRINGER INGELHEIM PHARMACEUTICAL'S PRODUCTS</i>	163
BRISTOL-MYERS SQUIBB COMPANY	163
BUSINESS OVERVIEW	163
PRODUCTS	163
<i>TABLE 112 BRISTOL-MYERS SQUIBB'S PHARMACEUTICAL PRODUCTS</i>	163
CEPHEID	164
BUSINESS OVERVIEW	164
PRODUCTS	164
<i>TABLE 113 CEPHEID DIAGNOSTIC'S PRODUCTS</i>	164
CREATIVE PEPTIDES	164
BUSINESS OVERVIEW	165
PRODUCTS	165
<i>TABLE 114 CREATIVE PEPTIDE'S DIAGNOSTIC PRODUCTS</i>	165
CRUCCELL NV	165
BUSINESS OVERVIEW	165
PRODUCTS	166
<i>TABLE 115 CRUCCELL'S VACCINE PRODUCTS</i>	166
CUBIST PHARMACEUTICALS (SEE MERCK)	166
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.	166
BUSINESS OVERVIEW	166
PRODUCTS	166

TOPIC	PAGE NO.
<i>TABLE 116 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS' DIAGNOSTIC PRODUCTS</i>	166
DIASORIN	167
BUSINESS OVERVIEW	167
PRODUCTS	168
<i>TABLE 117 DIASORIN DIAGNOSTIC'S PRODUCTS</i>	168
FIRST DIAGNOSTIC CORP.	169
BUSINESS OVERVIEW	169
PRODUCTS	169
<i>TABLE 118 FIRST DIAGNOSTIC'S PRODUCTS</i>	169
FOCUS DIAGNOSTICS	169
BUSINESS OVERVIEW	170
PRODUCTS	170
<i>TABLE 119 FOCUS DIAGNOSTIC'S PRODUCTS</i>	170
FOREST LABORATORIES (SEE ALLERGAN)	170
GILEAD SCIENCES INC.	170
BUSINESS OVERVIEW	171
PRODUCTS	171
<i>TABLE 120 GILEAD SCIENCE'S PHARMACEUTICAL PRODUCTS</i>	171
GLAXOSMITHKLINE	171
BUSINESS OVERVIEW	171
PRODUCTS	172
<i>TABLE 121 GLAXOSMITHKLINE PHARMACEUTICAL'S VACCINE PRODUCTS</i>	172
HOLOGIC INC.	173
BUSINESS OVERVIEW	173
PRODUCTS	173
<i>TABLE 122 HOLOGIC DIAGNOSTIC'S PRODUCTS</i>	173
HOME ACCESS HEALTH CORP.	174
BUSINESS OVERVIEW	174
PRODUCTS	174
<i>TABLE 123 HOME ACCESS HEALTH'S DIAGNOSTICS PRODUCTS</i>	174
IDENIX PHARMACEUTICALS (SEE MERCK)	174
IMMUNOSTICS INC.	174
BUSINESS OVERVIEW	174
PRODUCTS	175
<i>TABLE 124 IMMUNOSTIC'S DIAGNOSTIC PRODUCTS</i>	175
JANSSEN THERAPEUTICS	175
BUSINESS OVERVIEW	175
PRODUCTS	175
<i>TABLE 125 JANSSEN THERAPEUTIC'S PHARMACEUTICAL PRODUCTS</i>	175
LUPIN PHARMACEUTICALS INC.	176
BUSINESS OVERVIEW	176
PRODUCTS	176
<i>TABLE 126 LUPIN'S PHARMACEUTICAL PRODUCTS</i>	176
MANGALAM DRUGS & ORGANICS LTD.	177
BUSINESS OVERVIEW	177
PRODUCTS	177
<i>TABLE 127 MANGALAM'S PHARMACEUTICAL PRODUCTS</i>	177

TOPIC	PAGE NO.
MEDMIRA INC	177
BUSINESS OVERVIEW	178
PRODUCTS	178
<i>TABLE 128 MEDMIRA'S DIAGNOSTIC PRODUCTS</i>	178
MELINTA THERAPEUTICS (FORMERLY RIB-X PHARMACEUTICALS)	178
BUSINESS OVERVIEW	178
MERCK & COMPANY INC.	179
BUSINESS OVERVIEW	179
PRODUCTS	179
<i>TABLE 129 MERCK'S VACCINE PRODUCTS</i>	179
<i>TABLE 130 MERCK'S PHARMACEUTICAL PRODUCTS</i>	180
MERIDIAN BIOSCIENCE INC.	180
BUSINESS OVERVIEW	180
PRODUCTS	181
<i>TABLE 131 MERIDIAN BIOSCIENCE'S DIAGNOSTIC PRODUCTS</i>	181
MYLAN PHARMACEUTICALS	181
BUSINESS OVERVIEW	181
PRODUCTS	182
<i>TABLE 132 MYLAN'S PHARMACEUTICAL PRODUCTS</i>	182
NOVARTIS CORP.	182
BUSINESS OVERVIEW	182
PRODUCTS	182
<i>TABLE 133 NOVARTIS' DIAGNOSTIC PRODUCTS</i>	182
<i>TABLE 134 NOVARTIS' PHARMACEUTICAL PRODUCTS</i>	183
ORASURE TECHNOLOGIES INC.	183
BUSINESS OVERVIEW	183
PRODUCTS	183
<i>TABLE 135 ORASURE'S DIAGNOSTIC PRODUCTS</i>	183
ORTHO CLINICAL DIAGNOSTICS	183
BUSINESS OVERVIEW	184
PRODUCTS	184
<i>TABLE 136 ORTHO'S CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	184
PARATEK PHARMACEUTICALS	184
BUSINESS OVERVIEW	184
PFIZER INC.	184
BUSINESS OVERVIEW	185
PRODUCTS	185
<i>TABLE 137 PFIZER'S VACCINE PRODUCTS</i>	185
<i>TABLE 138 PFIZER'S PHARMACEUTICAL PRODUCTS</i>	185
PRINCETON BIOMEDITECH CORP.	186
BUSINESS OVERVIEW	186
PRODUCTS	186
<i>TABLE 139 PRINCETON BIOMEDICTECH'S DIAGNOSTIC PRODUCTS</i>	186
PROTEIN SCIENCES CORP.	186
BUSINESS OVERVIEW	187
QUIDEL CORP.	187
BUSINESS OVERVIEW	187

TOPIC	PAGE NO.
PRODUCTS	187
<i>TABLE 140 QUIDEL'S DIAGNOSTIC PRODUCTS</i>	187
QIAGEN N.V.	188
BUSINESS OVERVIEW	188
PRODUCTS	188
<i>TABLE 141 QIAGEN'S DIAGNOSTIC PRODUCTS</i>	188
REMEL/THERMOFISHER SCIENTIFIC	188
BUSINESS OVERVIEW	188
PRODUCTS	189
<i>TABLE 142 REMEL'S DIAGNOSTIC PRODUCTS</i>	189
ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.)	189
BUSINESS OVERVIEW	189
PRODUCTS	190
<i>TABLE 143 ROCHE'S DIAGNOSTIC PRODUCTS</i>	190
<i>TABLE 144 ROCHE'S PHARMACEUTICAL PRODUCTS</i>	190
ROMARK LABORATORIES	191
BUSINESS OVERVIEW	191
SANDOZ	191
BUSINESS OVERVIEW	191
PRODUCTS	191
<i>TABLE 145 SANDOZ'S PHARMACEUTICAL PRODUCTS</i>	191
SANOFI PASTEUR	192
BUSINESS OVERVIEW	192
PRODUCTS	192
<i>TABLE 146 SANOFI PASTEUR'S VACCINE PRODUCTS</i>	192
SCICLONE PHARMACEUTICALS	193
BUSINESS OVERVIEW	193
PRODUCTS	193
<i>TABLE 147 SCICLONE'S PHARMACEUTICAL PRODUCTS</i>	193
SHANGHAI KEHUA BIO-ENGINEERING CO. LTD.	193
BUSINESS OVERVIEW	193
PRODUCTS	194
<i>TABLE 148 SHANGHAI KEHUA'S DIAGNOSTIC PRODUCTS</i>	194
STANDARD DIAGNOSTICS INC.	194
BUSINESS OVERVIEW	194
PRODUCTS	195
<i>TABLE 149 STANDARD DIAGNOSTICS' DIAGNOSTIC PRODUCTS</i>	195
TETRAPHASE PHARMACEUTICALS	195
THE MEDICINE COMPANY	196
BUSINESS OVERVIEW	196
PRODUCTS	196
<i>TABLE 150 THE MEDICINE COMPANY'S PHARMACEUTICALS</i>	196
TRINITY BIOTECH PLC	196
BUSINESS OVERVIEW	196
PRODUCTS	197
<i>TABLE 151 TRINITY BIOTECH'S DIAGNOSTIC PRODUCTS</i>	197
VERTEX PHARMACEUTICALS	197

TOPIC	PAGE NO.
BUSINESS OVERVIEW	198
PRODUCTS	198
<i>TABLE 152 VERTEX'S PHARMACEUTICAL PRODUCTS</i>	198
VIIV HEALTHCARE	198
BUSINESS OVERVIEW	198
PRODUCTS	199
<i>TABLE 153 VIIV HEALTHCARE'S PHARMACEUTICAL PRODUCTS</i>	199
ZEUS SCIENTIFIC	199
BUSINESS OVERVIEW	199
PRODUCTS	200
<i>TABLE 154 ZEUS SCIENTIFIC'S DIAGNOSTIC PRODUCTS</i>	200
CHAPTER 11 APPENDIX A COMPANY LISTINGS BY TYPE	202
<i>TABLE 155 COMPANY LISTINGS BY TYPE, COMPANY, INDICATION AND NAME</i>	202

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	7
TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)	11
TABLE 2 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)	12
TABLE 3 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)	20
TABLE 4 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 (\$ MILLIONS)	21
TABLE 5 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	21
TABLE 6 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 (\$ MILLIONS)	23
TABLE 7 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 (\$ MILLIONS)	27
TABLE 8 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE, THROUGH 2021 (\$ MILLIONS)	27
TABLE 9 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES	30
TABLE 10 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES	31
TABLE 11 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS IN THE U.S.	32
TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS, TO 4 YEARS TO 6 YEARS IN THE U.S.	32
TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 YEARS TO 18 YEARS IN THE U.S.	33
TABLE 14 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2014	37
TABLE 15 REGIONAL MARKETS FOR VACCINES, THROUGH 2021 (\$ MILLIONS)	38
TABLE 16 AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	40
TABLE 17 EMRA MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	40
TABLE 18 ASIAN MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 (\$ MILLIONS)	41
TABLE 19 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	46
TABLE 20 PATENT EXPIRY BY PRODUCT, INDICATION, MANUFACTURER AND DATE OF PATENT EXPIRY	47
TABLE 21 GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	48
TABLE 22 GLOBAL MARKET SHARE FOR HEPATITIS B AND C DIAGNOSTIC PRODUCT BY TYPE OF TEST AND REVENUES, 2015 (\$ MILLIONS/%)	49
TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2015	49
TABLE 24 GLOBAL MARKET FOR HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2015 (\$ MILLIONS/RANK)	51
TABLE 25 PHARMACEUTICALS FOR THE TREATMENT OF HEPATITIS B AND C, 2015	53
TABLE 26 GLOBAL MARKET FOR HBV AND HCV PHARMACEUTICALS, THROUGH 2021 (\$ MILLIONS)	54
TABLE 27 GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	55

TABLE HEADING	PAGE NO.
TABLE 28 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HSV BY BRAND NAME, TYPE AND MANUFACTURER, 2015	56
TABLE 29 DRUGS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER	57
TABLE 30 GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	58
TABLE 31 COMBINATION DRUGS APPROVED FOR HAART	59
TABLE 32 GLOBAL MARKET FOR HPV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	63
TABLE 33 CANCERS LINKED TO HPV INFECTION, BY TYPE AND PERCENT OF FREQUENCY	63
TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2015	64
TABLE 35 DRUGS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME AND MANUFACTURER	65
TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE, 2015	69
TABLE 37 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)	70
TABLE 38 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	70
TABLE 39 REGIONAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	71
TABLE 40 REGIONAL MARKET FOR VIRAL DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)	73
TABLE 41 REGIONAL MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	73
TABLE 42 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)	74
TABLE 43 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)	74
TABLE 44 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)	76
TABLE 45 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)	77
TABLE 46 CURRENTLY USED HEPATITIS DRUGS IN THE SOUTHEAST ASIAN REGION, BY PERCENT OF USE, 2012*	78
TABLE 47 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)	80
TABLE 48 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)	81
TABLE 49 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES	83
TABLE 50 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	84
TABLE 51 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2021 (\$ MILLIONS)	84
TABLE 52 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2021 (\$ MILLIONS)	85
TABLE 53 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND MANUFACTURER, 2015	87
TABLE 54 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA	88
TABLE 55 GONORRHEA DIAGNOSTIC PRODUCT AND MANUFACTURERS	89

TABLE HEADING	PAGE NO.
TABLE 56 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS	90
TABLE 57 STAGES OF SYPHILIS	91
TABLE 58 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012	92
TABLE 59 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	95
TABLE 60 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 (\$ MILLIONS)	96
TABLE 61 ANTIBIOTICS: YEAR OF INTRODUCTION, YEAR OF RESISTANCE OBSERVED, MODE OF ACTION AND TARGET SPECIES	97
TABLE 62 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009* (POUNDS/%)	103
TABLE 63 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED	104
TABLE 64 REGIONAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	106
TABLE 65 AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	108
TABLE 66 AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	108
TABLE 67 AMERICAS MARKET FOR BACTERIAL INFECTION PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	109
TABLE 68 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	110
TABLE 69 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	110
TABLE 70 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	111
TABLE 71 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	111
TABLE 72 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	112
TABLE 73 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	113
TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES	115
TABLE 75 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	117
TABLE 76 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)	118
TABLE 77 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2015	118
TABLE 78 GLOBAL MARKET FOR MALARIAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	119
TABLE 79 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	120
TABLE 80 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	121
TABLE 81 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	122
TABLE 82 AMERICAS MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	122
TABLE 83 EMRA MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	122

TABLE HEADING	PAGE NO.
TABLE 84 EMRA MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	123
TABLE 85 EMRA MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	123
TABLE 86 ASIAN MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	124
TABLE 87 ASIAN MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	124
TABLE 88 ASIAN MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 (\$ MILLIONS)	125
TABLE 89 CURRENT AND PARASITIC PHARMACEUTICALS WITH TRADE NAME, GENERIC NAME, MANUFACTURER AND AREA OF TREATMENT, 2014	125
TABLE 90 FDA-APPROVED PHARMACEUTICALS TO TREAT HCV, 2011-2015	128
TABLE 91 PHARMACEUTICALS IN CLINICAL TRIALS FOR HCV, 2015	129
TABLE 92 PHASE II & III PIPELINE FOR MALARIAL TREATMENTS, 2015	131
TABLE 93 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2015	133
TABLE 94 U.S. PHARMACEUTICAL PATENT EXPIRY, 2010-2031	139
TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, JAN. 2015 TO SEPT. 2015	140
TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PRODUCT PATENTS BY COMPANY, JAN. 2015 TO SEPT. 2015	148
TABLE 97 PATENTS ISSUED FOR VACCINE AND TREATMENT OF INFECTIOUS DISEASES BY DISEASE, JAN. 2015 TO SEPT. 2015 (NUMBER/%)	150
TABLE 98 INFECTIOUS DISEASES VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN JAN. 2015 AND SEPT. 2015 (%)	151
TABLE 99 ABBOTT PHARMACEUTICAL PRODUCTS	153
TABLE 100 ABBOTT DIAGNOSTIC PRODUCTS	153
TABLE 101 ABBVIE PHARMACEUTICAL PRODUCTS	154
TABLE 102 ALLERGAN PHARMACEUTICAL PRODUCTS	155
TABLE 103 ALERE DIAGNOSTIC PRODUCTS	156
TABLE 104 ALFA SCIENTIFIC DESIGNS' DIAGNOSTIC PRODUCTS	157
TABLE 105 ATLAS LINK BIOTECH DIAGNOSTIC'S PRODUCTS	158
TABLE 106 ASTRAZENECA PHARMACEUTICAL'S PRODUCTS	159
TABLE 107 BAXTER PHARMACEUTICAL'S PRODUCTS	160
TABLE 108 BAYER PHARMACEUTICAL'S PRODUCTS	160
TABLE 109 BECTON DICKINSON DIAGNOSTIC'S PRODUCTS	161
TABLE 110 BIO-RAD DIAGNOSTIC'S PRODUCTS	162
TABLE 111 BOEHRINGER INGELHEIM PHARMACEUTICAL'S PRODUCTS	163
TABLE 112 BRISTOL-MYERS SQUIBB'S PHARMACEUTICAL PRODUCTS	163
TABLE 113 CEPHEID DIAGNOSTIC'S PRODUCTS	164
TABLE 114 CREATIVE PEPTIDE'S DIAGNOSTIC PRODUCTS	165
TABLE 115 CRUCCELL'S VACCINE PRODUCTS	166
TABLE 116 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS' DIAGNOSTIC PRODUCTS	166
TABLE 117 DIASORIN DIAGNOSTIC'S PRODUCTS	168
TABLE 118 FIRST DIAGNOSTIC'S PRODUCTS	169
TABLE 119 FOCUS DIAGNOSTIC'S PRODUCTS	170
TABLE 120 GILEAD SCIENCE'S PHARMACEUTICAL PRODUCTS	171
TABLE 121 GLAXOSMITHKLINE PHARMACEUTICAL'S VACCINE PRODUCTS	172

TABLE HEADING	PAGE NO.
TABLE 122 HOLOGIC DIAGNOSTIC'S PRODUCTS	173
TABLE 123 HOME ACCESS HEALTH'S DIAGNOSTICS PRODUCTS	174
TABLE 124 IMMUNOSTIC'S DIAGNOSTIC PRODUCTS	175
TABLE 125 JANSSEN THERAPEUTIC'S PHARMACEUTICAL PRODUCTS	175
TABLE 126 LUPIN'S PHARMACEUTICAL PRODUCTS	176
TABLE 127 MANGALAM'S PHARMACEUTICAL PRODUCTS	177
TABLE 128 MEDMIRA'S DIAGNOSTIC PRODUCTS	178
TABLE 129 MERCK'S VACCINE PRODUCTS	179
TABLE 130 MERCK'S PHARMACEUTICAL PRODUCTS	180
TABLE 131 MERIDIAN BIOSCIENCE'S DIAGNOSTIC PRODUCTS	181
TABLE 132 MYLAN'S PHARMACEUTICAL PRODUCTS	182
TABLE 133 NOVARTIS' DIAGNOSTIC PRODUCTS	182
TABLE 134 NOVARTIS' PHARMACEUTICAL PRODUCTS	183
TABLE 135 ORASURE'S DIAGNOSTIC PRODUCTS	183
TABLE 136 ORTHO'S CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS	184
TABLE 137 PFIZER'S VACCINE PRODUCTS	185
TABLE 138 PFIZER'S PHARMACEUTICAL PRODUCTS	185
TABLE 139 PRINCETON BIOMEDICTECH'S DIAGNOSTIC PRODUCTS	186
TABLE 140 QUIDEL'S DIAGNOSTIC PRODUCTS	187
TABLE 141 QIAGEN'S DIAGNOSTIC PRODUCTS	188
TABLE 142 REMEL'S DIAGNOSTIC PRODUCTS	189
TABLE 143 ROCHE'S DIAGNOSTIC PRODUCTS	190
TABLE 144 ROCHE'S PHARMACEUTICAL PRODUCTS	190
TABLE 145 SANDOZ'S PHARMACEUTICAL PRODUCTS	191
TABLE 146 SANOFI PASTEUR'S VACCINE PRODUCTS	192
TABLE 147 SCICLONE'S PHARMACEUTICAL PRODUCTS	193
TABLE 148 SHANGHAI KEHUA'S DIAGNOSTIC PRODUCTS	194
TABLE 149 STANDARD DIAGNOSTICS' DIAGNOSTIC PRODUCTS	195
TABLE 150 THE MEDICINE COMPANY'S PHARMACEUTICALS	196
TABLE 151 TRINITY BIOTECH'S DIAGNOSTIC PRODUCTS	197
TABLE 152 VERTEX'S PHARMACEUTICAL PRODUCTS	198
TABLE 153 VIIV HEALTHCARE'S PHARMACEUTICAL PRODUCTS	199
TABLE 154 ZEUS SCIENTIFIC'S DIAGNOSTIC PRODUCTS	200
TABLE 155 COMPANY LISTINGS BY TYPE, COMPANY, INDICATION AND NAME	202

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)	7
FIGURE 1 GLOBAL IMMUNIZATION COVERAGE, 2014 (%)	14
FIGURE 2 VACCINE MANUFACTURING PROCESS	35
FIGURE 3 GLOBAL VACCINE MANUFACTURING MARKET, 2014 (%)	35
FIGURE 4 REGIONAL MARKET SHARE FOR VACCINES, 2016 AND 2021 (%)	38
FIGURE 5 GLOBAL MARKET SHARE FOR TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET, 2015 (%)	52
FIGURE 6 REGIONAL MARKET SHARE FOR VIRAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)	72
FIGURE 7 REGIONAL MARKET SHARE FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)	106
FIGURE 8 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)	120
FIGURE 9 RESEARCH LANDSCAPE FOR HBV PHARMACEUTICALS BY TYPE, 2015 (%)	130